Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 10/2023

09.09.2023 | Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

COVID Vaccination as a Strategy for Cardiovascular Disease Prevention

verfasst von: Michael P. Fundora, Satoshi Kamidani, Matthew E. Oster

Erschienen in: Current Cardiology Reports | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cardiovascular (CV) disease is a known complication of SARS-CoV-2 infection. A clear benefit of COVID-19 vaccination is a reduction mortality; however, COVID-19 vaccination may also prevent cardiovascular disease (CVD). We aim to describe CV pathology associated with SARS-CoV-2 infection and describe how COVID-19 vaccination is a strategy for CVD prevention.

Recent Findings

The risks and benefits of COVID-19 vaccination have been widely studied. Analysis of individuals with and without pre-existing CVD has shown that COVID-19 vaccination can prevent morbidity associated with SARS-CoV-2 infection and reduce mortality.

Summary

COVID-19 vaccination is effective in preventing myocardial infarction, cerebrovascular events, myopericarditis, and long COVID, all associated with CVD risk factors. Vaccination reduces mortality in patients with pre-existing CVD. Further study investigating ideal vaccination schedules for individuals with CVD should be undertaken to protect this vulnerable group and address new risks from variants of concern.
Literatur
1.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8.PubMedCrossRef
2.
Hall EJ, Das SR, Ayers C, Bradley SM, Elkind M, Hall JL, et al. Longitudinal trends in cardiovascular complications among patients hospitalized for Covid-19 infection: a national multi-center analysis. Circulation. 2022;146(Suppl_1):A10406-A.
3.
• Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–90. https://​doi.​org/​10.​1038/​s41591-022-01689-3. Findings from this study demonstrated the increased risks of a multitude of adverse cardiovascular outcomes associated with COVID-19.
4.
Giustino G, Pinney SP, Lala A, Reddy VY, Johnston-Cox HA, Mechanick JI, et al. Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC focus seminar. J Am Coll Cardiol. 2020;76(17):2011–23.PubMedPubMedCentralCrossRef
5.
Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377:e069590. https://​doi.​org/​10.​1136/​bmj-2021-069590.
6.
Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Connolly AMF. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021;398(10300):599–607.
7.
Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA. 2022;328(9):887–9.PubMedPubMedCentralCrossRef
8.
Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533–46.PubMedPubMedCentralCrossRef
9.
Luetkens JA, Isaak A, Zimmer S, Nattermann J, Sprinkart AM, Boesecke C, et al. Diffuse myocardial inflammation in COVID-19 associated myocarditis detected by multiparametric cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2020;13(5):e010897.
10.
Modin D, Claggett B, Sindet-Pedersen C, Lassen MCH, Skaarup KG, Jensen JUS, et al. Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction. Circulation. 2020;142(21):2080–2.PubMedPubMedCentralCrossRef
11.
12.
Vasudeva R, Challa A, Al Rifai M, Polana T, Duran B, Vindhyal M, et al. Prevalence of cardiovascular diseases in COVID-19 related mortality in the United States. Prog Cardiovasc Dis. 2022.
13.
Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13378.
14.
Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13362.
15.
Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215.
16.
Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–22.PubMedPubMedCentralCrossRef
17.
Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2023.
18.
Hayes LD, Ingram J, Sculthorpe NF. More than 100 persistent symptoms of SARS-CoV-2 (long COVID): a scoping review. Front Med. 2021;8: 750378.CrossRef
19.
Simone A, Herald J, Chen A, Nayak R, Shen AYJ, Lee MS. Exacerbation of pre-existing cardiovascular disease following COVID-19 mRNA vaccination. Circulation. 2022;146(Suppl_1):A11371-A.
20.
Peiris S, Ordunez P, DiPette D, Padwal R, Ambrosi P, Toledo J, et al. Cardiac manifestations in patients with COVID-19: a scoping review. Global Heart. 2022;17(1).
21.
Polito MV, Silverio A, Bellino M, Iuliano G, Di Maio M, Alfano C, et al. Cardiovascular involvement in COVID-19: what sequelae should we expect? Cardiol Ther. 2021;10(2):377–96.PubMedPubMedCentralCrossRef
22.
Wang W, Wang C-Y, Wang SI, Wei JCC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619.
23.
24.
Woodruff RC, Garg S, George MG, Patel K, Jackson SL, Loustalot F, et al. Acute cardiac events during COVID-19-associated hospitalizations. J Am Coll Cardiol. 2023;81(6):557–69.PubMedPubMedCentralCrossRef
25.
Lombardi CM, Carubelli V, Iorio A, Inciardi RM, Bellasi A, Canale C, et al. Association of troponin levels with mortality in Italian patients hospitalized with coronavirus disease 2019: results of a multicenter study. JAMA Cardiol. 2020;5(11):1274–80.PubMedCrossRef
26.
Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. J Am Coll Cardiol. 2020;76(10):1244–58.PubMedPubMedCentralCrossRef
27.
Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–64.PubMedCrossRef
28.
Hall EJ, Ayers CR, Kolkailah AA, Rutan C, Walchok J, Williams IV JH, et al. Longitudinal trends in cardiovascular risk factor profiles and complications among patients hospitalized for COVID-19 infection: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circ Cardiovasc Qual Outcomes. 2023:e009652.
29.
Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5(3).
30.
Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324(8):799–801.PubMedPubMedCentralCrossRef
31.
Lewek J, Jatczak-Pawlik I, Maciejewski M, Jankowski P, Banach M. COVID-19 and cardiovascular complications–preliminary results of the LATE-COVID study. Arch Med Sci. 2021;17(3):818.PubMedPubMedCentralCrossRef
32.
Perego E, Callard F, Stras L, Melville-Johannesson B, Pope R, Alwan N. Why we need to keep using the patient made term “Long Covid. 2020.
33.
Mendelson M, Nel J, Blumberg L, Madhi S, Dryden M, Stevens W, et al. Long-COVID: an evolving problem with an extensive impact. S Afr Med J. 2021;111(1):10–2.
34.
Sorokin AV, Karathanasis SK, Yang ZH, Freeman L, Kotani K, Remaley AT. COVID-19—associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J. 2020;34(8):9843.PubMedCrossRef
35.
Roccaforte V, Daves M, Lippi G, Spreafico M, Bonato C. Altered lipid profile in patients with COVID-19 infection. J Lab Precis Med. 2021;6:2-.
36.
Chen Y, Yao H, Zhang N, Wu J, Gao S, Guo J, et al. Proteomic analysis identifies prolonged disturbances in pathways related to cholesterol metabolism and myocardium function in the COVID-19 recovery stage. J Proteome Res. 2021;20(7):3463–74.PubMedCrossRef
37.
Jone PN, John A, Oster ME, Allen K, Tremoulet AH, Saarel EV, et al. SARS-CoV-2 infection and associated cardiovascular manifestations and complications in children and young adults: a scientific statement from the American Heart Association. Circulation. 2022;145(19):e1037–52.PubMedCrossRef
38.
Lasa JJ, Alali A, Anders M, Tume SC, Muscal E, Tejtel SKS, et al. Cardiovascular sequelae from COVID-19: perspectives from a paediatric cardiac ICU. Cardiol Young. 2023;33(1):52–9.CrossRef
39.
Williams N, Radia T, Harman K, Agrawal P, Cook J, Gupta A. COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2021;180:689–97.PubMedCrossRef
40.
Fremed MA, Healy EW, Choi NH, Cheung EW, Choudhury TA, Jiang P, et al. Elevated cardiac biomarkers and outcomes in children and adolescents with acute COVID-19. Cardiol Young. 2023;33(2):183–9.PubMedCrossRef
41.
Guner Ozenen G, Akaslan Kara A, Kiymet E, Boncuoglu E, Sahinkaya S, Cem E, et al. The evaluation of troponin I levels and myocarditis in children with COVID-19: a pediatric single-center experience. Pediatr Cardiol. 2023;44(4):873–81.PubMedCrossRef
42.
Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA Cardiol. 2021;6(9):1078–87.PubMedPubMedCentralCrossRef
43.
Clark DE, Parikh A, Dendy JM, Diamond AB, George-Durrett K, Fish FA, et al. COVID-19 myocardial pathology evaluation in athletes with cardiac magnetic resonance (COMPETE CMR). Circulation. 2021;143(6):609–12.PubMedCrossRef
44.
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med. 2020;383(4):334–46.PubMedCrossRef
45.
Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347–58.PubMedCrossRef
46.
Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr. 2021;175(8):837–45.PubMedCrossRef
47.
Gilboa SM, Devine OJ, Kucik JE, Oster ME, Riehle-Colarusso T, Nembhard WN, et al. Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation. 2016;134(2):101–9.PubMedPubMedCentralCrossRef
48.
Ehwerhemuepha L, Roth B, Patel AK, Heutlinger O, Heffernan C, Arrieta AC, et al. Association of congenital and acquired cardiovascular conditions with COVID-19 severity among pediatric patients in the US. JAMA Netw Open. 2022;5(5):e2211967-e.
49.
Pagnesi M, Baldetti L, Beneduce A, Calvo F, Gramegna M, Pazzanese V, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020;106(17):1324–31.PubMedCrossRef
50.
Broberg CS, Kovacs AH, Sadeghi S, Rosenbaum MS, Lewis MJ, Carazo MR, et al. COVID-19 in adults with congenital heart disease. J Am Coll Cardiol. 2021;77(13):1644–55.PubMedPubMedCentralCrossRef
51.
Lewis MJ, Anderson BR, Fremed M, Argenio M, Krishnan U, Weller R, et al. Impact of coronavirus disease 2019 (COVID-19) on patients with congenital heart disease across the lifespan: the experience of an academic congenital heart disease center in New York City. J Am Heart Assoc. 2020;9(23):e017580.
52.
Ferrero P, Piazza I, Ciuffreda M. COVID-19 in adult patients with CHD: a matter of anatomy or comorbidities? Cardiol Young. 2020;30(8):1196–8.PubMedCrossRef
53.
Wang F, Liu A, Brophy JM, Cohen S, Abrahamowicz M, Paradis G, et al. Determinants of survival in older adults with congenital heart disease newly hospitalized for heart failure. Circ Heart Fail. 2020;13(8):e006490.
54.
Downing KF, Simeone RM, Oster ME, Farr SL. Critical illness among patients hospitalized with acute COVID-19 with and without congenital heart defects. Circulation. 2022;145(15):1182–4.PubMedPubMedCentralCrossRef
55.
56.
57.
58.
59.
Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. JAMA Netw Open. 2021;4(8):e2122240-e.
60.
61.
Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of vaccination on transmission of SARS-CoV-2. N Engl J Med. 2021;385(18):1718–20.PubMedCrossRef
62.
Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of vaccination on household transmission of SARS-CoV-2 in England. N Engl J Med. 2021;385(8):759–60.PubMedCrossRef
63.
64.
65.
Núñez-Gil IJ, Feltes G, Viana-Llamas MC, Raposeiras-Roubin S, Romero R, Alfonso-Rodríguez E, et al. Post-COVID-19 symptoms and heart disease: incidence, prognostic factors, outcomes and vaccination: results from a multi-center international prospective registry (HOPE 2). J Clin Med. 2023;12(2):706.PubMedPubMedCentralCrossRef
66.
67.
Parodi JB, Indavere A, Jacob PB, Toledo GC, Micali RG, Waisman G, et al. Impact of COVID-19 vaccination in post-COVID cardiac complications. Vaccine. 2023;41(8):1524–8.PubMedPubMedCentralCrossRef
68.
•• Jiang J, Chan L, Kauffman J, Narula J, Charney AW, Oh W, et al. Impact of vaccination on major adverse cardiovascular events in patients with COVID-19 infection. J Am Coll Cardiol. 2023;81(9):928–30. This article demonstrates that COVID-19 vaccination not only protects individuals from contracting COVID-19, but in instances where an individual does contract COVID-19 the likelihood of major adverse cardiovascular events is reduced.
69.
Ye X, Yan VK, Yiu HHE, Shami JJ, Kang W, Ma T, et al. BNT162b2 or CoronaVac vaccinations are associated with a lower risk of myocardial infarction and stroke after SARS‐CoV‐2 infection among patients with cardiovascular disease. J Am Heart Assoc. 2022:e029291.
70.
Whiteley WN, Ip S, Cooper JA, Bolton T, Keene S, Walker V, et al. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: a population-based cohort study of 46 million adults in England. PLoS Med. 2022;19(2):e1003926.
71.
Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410–22.PubMedCrossRef
72.
Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years—United States, July–December 2021. Morb Mortal Wkly Rep. 2022;71(2):52.CrossRef
73.
• Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. Jama. 2022;327(4):331–40. https://​doi.​org/​10.​1001/​jama.​2021.​24110. This manuscript details the incidence and clinical findings of acute myocarditis associated with COVID-19 vaccination from cases reported to the US Vaccine Adverse Event Reporting System.
74.
Chin SE, Bhavsar SM, Corson A, Ghersin ZJ, Kim HS. Cardiac complications associated with COVID-19, MIS-C, and mRNA COVID-19 vaccination. Pediatr Cardiol. 2022;43(3):483–8.PubMedPubMedCentralCrossRef
75.
Block JP, Boehmer TK, Forrest CB, Carton TW, Lee GM, Ajani UA, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination—PCORnet, United States, january 2021–January 2022. Morb Mortal Wkly Rep. 2022;71(14):517.CrossRef
76.
77.
Hause AM, Marquez P, Zhang B, Myers TR, Gee J, Su JR, et al. COVID-19 mRNA vaccine safety among children aged 6 months–5 years—United States, June 18, 2022–August 21, 2022. Morb Mortal Wkly Rep. 2022;71(35):1115.CrossRef
78.
79.
80.
Noori M, Nejadghaderi SA, Arshi S, Carson-Chahhoud K, Ansarin K, Kolahi AA, et al. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Rev Med Vir. 2022;32(2):e2277. https://​doi.​org/​10.​1002/​rmv.​2277.
81.
Bayart JL, Douxfils J, Gillot C, David C, Mullier F, Elsen M, et al. Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers. Vaccines. 2021;9(10):1092.PubMedPubMedCentralCrossRef
82.
83.
84.
Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379:e072141. https://​doi.​org/​10.​1136/​bmj-2022-072141.
85.
86.
Metadaten
Titel
COVID Vaccination as a Strategy for Cardiovascular Disease Prevention
verfasst von
Michael P. Fundora
Satoshi Kamidani
Matthew E. Oster
Publikationsdatum
09.09.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 10/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01950-2

Weitere Artikel der Ausgabe 10/2023

Current Cardiology Reports 10/2023 Zur Ausgabe

Echocardiography (JM Gardin and AH Waller, Section Editors)

Echocardiographic Evaluation of Cardiac Masses

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Improving Hypertension Control in Vulnerable Populations Around the World

Hypertension (DS Geller and DL Cohen, Section Editors)

The Promise and Illusion of Continuous, Cuffless Blood Pressure Monitoring

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Challenges in Cardiovascular Imaging in Women with Breast Cancer

Hypertension (DS Geller and DL Cohen, Section Editors)

Current and Developing Technologies for BP Monitoring

Valvular Heart Disease (TL Kiefer, Section Editor)

Aortic Regurgitation: Review of the Diagnostic Criteria and the Management Guidelines

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen